Lactobacillus acidophilus veterinary-grade API intended for direct-compression oral tablets is supplied as a lyophilized, standardised concentrate on a maltodextrin or trehalose carrier, with viable count expressed in colony-forming units per gram rather than as a simple chemical purity. This format is selected because direct compression preserves the viability of the non-spore-forming, facultative anaerobe better than wet granulation or drying steps. The nonsterile oral product is released against USP 61 and USP 62 for microbial limits, with water activity not exceeding 0.20 per USP 922 and loss on drying not exceeding 5.0% per USP 921; where the tablet is marketed as a direct-fed microbial rather than a drug, FDA 21 CFR 507.22 animal food cGMP and the AAFCO direct-fed microorganisms list apply. Injectable formulations are excluded from this application route because live bacterial cells cannot be terminally sterilized by moist heat at 121°C and cannot be filtered through sterilizing-grade membranes; no veterinary pharmacopoeial monograph currently supports parenteral administration of live Lactobacillus acidophilus. The addition ratio is calculated from the lot potency. For a lot standardised to 1×10¹⁰ CFU/g, a target of 1×10⁹ CFU per 500 mg tablet requires 100 mg API, or 20% w/w. If the potency falls to 5×10⁹ CFU/g, the API mass rises to 200 mg per tablet, or 40% w/w, which reduces compressibility and may require rebalancing filler excipients. Production begins with geometric dilution of the API into microcrystalline cellulose PH-102 (10–15% w/w) in a 200 L V-blender; dicalcium phosphate dihydrate (10–20% w/w), crospovidone (1–2% w/w), and colloidal silicon dioxide (0.5–1.0% w/w) are added before low-shear blending at 15–20 rpm for 15–20 min. Sodium stearyl fumarate at 0.5–1.0% w/w is preferred over magnesium stearate because stearate coatings can prolong disintegration in low-moisture tablets. Compression on a 16-station rotary tablet press with 8 mm round tooling uses precompression of 4–6 kN and main compression of 10–14 kN; published technical bulletins for lactobacillus tablets indicate that main compression forces above 15 kN can generate 0.5–1.0 log viability loss through shear on the lyophilized carrier. Finished products are cold-form aluminium/aluminium blister-packed with desiccant, and terminal formats include canine oral tablets, feline chewable tablets, and calf oral tablets.

What Limits Drinking-Water and Drench Solution Stability When Chlorine Is Present?

Chlorinated mains water is the main process failure point in water-dispersible Lactobacillus acidophilus powder and drench solution production. Free chlorine above 0.2 mg/L can reduce viable counts by more than 1 log within 60 min; at 0.5 mg/L the reduction is rapid enough to make label claims unreachable. Formulators therefore pre-treat water with sodium thiosulfate at 0.05–0.10 g/L or ascorbic acid at 0.1–0.3 g/L, and verify residual chlorine before hydration. The addition ratio is set as CFU per litre of final drinking water. A 1×10¹⁰ CFU/g API lot used to deliver 1×10⁸–1×10⁹ CFU/L requires 0.01–0.10 g/L final concentration. With a 1:128 Venturi proportioner, the stock solution must be 1.28–12.8 g/L. The stock should be prepared in water at ≤25°C and used within 4–6 h; prolonged hydration of the maltodextrin carrier and pH drift reduce viability. Production uses a low-shear propeller mixer at 100–150 rpm to disperse the powder, because high-shear rotor-stator mixing creates cavitation and local temperature rise that damage bacterial cells. The slurry is metered into a stock tank through a diaphragm pump, and recirculation line velocity is kept below 0.5 m/s. Lines are sanitized with peracetic acid 50–100 ppm followed by treated-water rinsing; steam sterilization of lines carrying live biological suspension is avoided because residual heat and condensate create uncontrolled conditions. Microbial enumeration follows ISO 15214:1998 with sample preparation according to ISO 6887-1:2017. In the EU the zootechnical additive status falls under Regulation (EC) No 1831/2003; in the US, FDA 21 CFR 507.22 applies to animal food use. Terminal product types include water-soluble sachets, foil-sealed concentrated oral solution jugs, and drench solutions for piglet, broiler, and layer operations.

Post-pellet vacuum coating and the 65°C conditioning threshold in pelleted feed premix

Feed pelleting is the most thermally destructive downstream process for non-spore-forming lactic acid bacteria. Conditioning of mash at 70–85°C for 15–60 s is common in broiler and pig feed lines, and Lactobacillus acidophilus should not be introduced before the pellet press under these conditions. The critical process boundary is a conditioner outlet temperature of approximately 65°C; published data for this specific strain and carrier configuration is limited, but industrial trials on non-encapsulated lactobacilli consistently show at least 1–2 log reduction at that threshold. The downstream production route therefore moves the API to post-pellet application. For a final feed count of 1×10⁶–1×10⁷ CFU/g, a 1×10¹⁰ CFU/g concentrate is applied at 0.1–1.0 kg/t. If an intermediate 1×10⁹ CFU/g premix is used, the inclusion rises to 1–10 kg/t. The calculation assumes the carrier has water activity below 0.20 and the pellets have been cooled to ≤40°C before coating. In post-pellet vacuum coating, a horizontal cylindrical coater with internal baffles and a liquid spray lance is charged with cooled pellets at 11–13% moisture. The Lactobacillus acidophilus concentrate is suspended in food-grade vegetable oil or medium-chain triglyceride at 5–10% w/w solids and sprayed at a rate that avoids pooling; the coated pellets are then held under reduced pressure for 3–5 min to draw the suspension into surface fissures. In dry electrostatic coating, a positively charged powder cloud is applied to grounded pellets carrying a 0.5–2.0% w/w oil or fat glaze to promote adhesion. No post-coating drying above 45°C is used, because this would reactivate the same thermal stress avoided by post-pellet application. Compliance includes EU Regulation 1831/2003, FDA 21 CFR 507.22, and AAFCO direct-fed microorganism definitions; enumeration follows ISO 15214:1998 with feed sampling according to ISO 6497:2002. Terminal finished product types include pelleted broiler starter, piglet creep feed, dairy transition feed, and extruded companion animal kibble; extruded kibble is coated only after extrusion and cooling because barrel temperatures of 90–120°C destroy the organism.

Two-piece hard capsule filling imposes a different set of viability constraints than direct compression. The capsule shell itself is a moisture reservoir: gelatin and HPMC capsules equilibrate at 13–16% water content under ambient conditions, and this water exchanges with the dry lyophilized blend. Filling rooms are therefore held at 25°C and 20–35% RH, and the active blend is required to have water activity below 0.20 (USP 922) and loss on drying below 5.0% (USP 921). The target fill is 1×10⁹ CFU per capsule. A 1×10¹⁰ CFU/g lot contributes 100 mg API per 300 mg fill weight in a size 0 capsule, i.e., 33.3% w/w. If the same capsule is filled with an 8×10⁹ CFU/g lot, the API mass rises to 125 mg, and the filler mass must fall from 200 mg to 175 mg, which alters powder bed compressibility and may require adjustment of the tamping force. Production uses low-shear tumble blending in a 50–100 L bin blender at 10–15 rpm for 15 min. The API is pre-blended with mannitol or microcrystalline cellulose in 3 geometric dilution steps before fumed silica at 0.5–1.0% w/w is added. Capsule filling is performed on a semi-automatic tamping-pin or dosator machine, with force set to the minimum that achieves ±5% fill weight variation; excessive tamping or dosator compression can rupture the lyophilized carrier and expose the organism to shell moisture. Compliance follows USP 61 and USP 62 for nonsterile oral dosage forms, with primary packaging controlled under ISO 15378:2017 where applicable. Terminal products include hard gelatin capsules, acid-resistant HPMC capsules, multi-strain companion animal capsules, and capsules packaged into cold-form blister cards with desiccant.

When oral paste for neonatal calves requires an anhydrous suspension rather than water-based syrup

Oral paste syringes for neonatal calves, lambs, and foals require a water-free base because added water in a syrup raises water activity above the threshold for bacterial metabolism and accelerates viability loss during ambient distribution. A typical addition provides 1×10⁹ CFU per 5–10 mL dose. With a 1×10¹⁰ CFU/g API, 100 mg API is dispersed per 10 mL, equivalent to 1% w/w if the paste density is approximately 1.0 g/mL; for a 5 mL dose the concentration becomes 2% w/w. Overages of 0.3–0.5 log may be added only after stability studies, because unsubstantiated overages increase label-claim variability and can complicate regulatory registration. The base is prepared in a vacuum planetary mixer. Medium-chain triglyceride or sunflower oil is loaded first. Fumed silica at 1.5–3.0% w/w and lecithin at 0.5–1.0% w/w are dispersed under low shear to form a thixotropic gel. The API is added as a dry powder through a sieve screen under vacuum, and mixing continues at 20–30 rpm for 10–15 min under −0.7 to −0.8 bar to remove entrained air. Temperature is maintained at ≤30°C throughout the dispersion. The finished paste is filled into plastic syringe barrels with LDPE plungers and sealed in aluminium-laminated pouches to exclude atmospheric moisture. The product is released according to USP 61 and USP 62; water activity is controlled below 0.60 per USP 922 to prevent metabolic activation. In the EU, the zootechnical additive route requires compliance with Regulation 1831/2003; in the US, FDA 21 CFR 507 animal food cGMP applies. Terminal products include calf scour management pastes, foal digestive support syringes, and lamb oral paste.

Dry compaction, spheronization, and the moisture ceiling for lactobacillus granules

Granular dosage forms for calf starter, colostrum replacers, and piglet creep feed cannot use conventional wet granulation with starch paste and tray drying at 50–60°C, because the combination of moisture and heat is lethal to the vegetative cells. Dry granulation by roller compaction is therefore used. The API addition is calculated from the final granule count. For a 2 g dose delivering 1×10⁹ CFU, a 1×10¹⁰ CFU/g lot contributes 100 mg API, or 5% w/w. If the terminal target is 1×10⁸ CFU/g, API inclusion falls to 1% w/w. The pre-blend contains mannitol or lactose, microcrystalline cellulose, crospovidone, and magnesium stearate; it is compacted on a roller compactor operating at low roll pressure and cooled to ≤30°C. The compacted ribbon is screened to 500–1,000 µm granules. Oversized material is recycled only once, because repeated compaction passes can reduce viability by 0.5–1.0 log per pass; published data for this specific roller-compactor configuration is limited, so process validation must confirm viability after recycle. Granules are packaged immediately in moisture-barrier jars or stick packs, and water activity is kept below 0.20 (USP 922). The enumeration method is ISO 15214:1998; sampling follows ISO 6497:2002 for feed applications. EU Regulation 1831/2003 and FDA 21 CFR 507.22 apply according to the label claim and target species. Terminal product types include calf starter granules, piglet creep granules, and water-reconstitutable oral granules for young ruminants.